Administered intramuscularly (IM) or intravenously (IV). For IV administration, it should be given as a bolus over no less than 15 seconds. Ensure proper aseptic technique.

Ketorolac inhibits prostaglandin synthesis by reversibly blocking the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. This results in analgesic, anti-inflammatory, and antipyretic effects.

• •Active peptic ulcer disease or gastrointestinal bleeding
• •History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
• •Advanced renal impairment
• •Coagulation disorders or patients at high risk of bleeding
• •Peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery
• •Concomitant use with other NSAIDs, aspirin, or probenecid
• •Pregnancy (especially third trimester) and lactation

Store below 30°C, protected from light. Do not freeze. Keep out of reach of children.

Symptoms may include abdominal pain, nausea, vomiting, lethargy, and drowsiness. Rare cases of severe gastrointestinal bleeding, acute renal failure, hypertension, and respiratory depression have been reported. Management is primarily supportive and symptomatic. Gastric lavage and activated charcoal may be considered if recent oral ingestion. Dialysis is not effective in removing Ketorolac due to high protein binding.

Pregnancy Category C (first and second trimester), Category D (third trimester). Contraindicated during labor and delivery, and in the third trimester due to risk of premature closure of ductus arteriosus and fetal renal dysfunction. Not recommended during lactation due to excretion in breast milk.